Brief: Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta
03/12/2025 12:32
Dec 3 (Reuters) - ADC Therapeutics SA ADCT.N: ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 PHASE 1B CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY SUPPORTING POTENTIAL BEST-IN-CLASS REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ADC THERAPEUTICS SA - LOTIS-7 TRIAL ON TRACK FOR COMPLETE ENROLLMENT IN 1H 2026 Source text: ID:nPn2vVl98a Further company coverage: ADCT.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview